Vertex, Inc. (NASDAQ:VERX) announced on Tuesday that president and CEO David DeStefano will step down from his roles effective November 10, 2025. Following an extensive search assisted by an ...

News headlines Vertex Pharmaceuticals (VRTX) is gaining traction with strong kidney data and regulatory advancements for its drug povetacicept. The company has raised its revenue guidance for 2025, ...

EHA: Vertex, CRISPR build case for gene-editing drug A gene-editing drug developed by CRISPR Therapeutics and Vertex Pharma has continued to show impressive results in clinical trial, with an update ...

In another departure from its core focus on genetic medicines, Vertex Pharma has agreed a $4.9 billion purchase of Alpine Immune Sciences, adding a mid-stage drug candidate for kidney disease IgA ...

BofA lowered the firm’s price target on Vertex Pharmaceuticals (VRTX) to $563 from $565 and keeps a Buy rating on the shares. The firm, which expects steady growth for the cystic fibrosis franchise in ...

Abstract: An efficient implicit representation of an n-vertex graph G in a family $\mathcal{F}$ of graphs assigns to each vertex of G a binary code of length O(log n) so that the adjacency between ...

Abstract: Anomaly detection is a fundamental task in hyperspectral image (HSI) processing. However, most existing methods rely on pixel feature vectors and overlook the relational structure ...

Investopedia contributors come from a range of backgrounds, and over 25 years there have been thousands of expert writers and editors who have contributed. Production efficiency is a point where ...

This price reflects trading activity during the overnight session on the Blue Ocean ATS, available 8 PM to 4 AM ET, Sunday through Thursday, when regular markets are closed.

Sales from two of Vertex Pharmaceuticals’ newest products appear to have dampened an earnings report that otherwise met or slightly exceeded expectations on Wall Street. Vertex recorded a little over ...